Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Featured trial
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

) and cytotoxic T- lymphocyte antigen-4 (CTLA-4), respectively. The current study is designed to evaluate the triple combination of sitravatinib plus NIVO/IPI in patients with solid tumor

systemic therapy
monoclonal antibodies
VEGFR2
tyrosine
carcinoma
  • 57 views
  • 15 Sep, 2020
  • 1 location
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

Background CTLA4 stands for cytotoxic T-lymphocyte antigen-4. It is a protein the body makes naturally to check its immune system from attacking itself. Some

  • 2 views
  • 10 Aug, 2022
  • 1 location
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1

hysterectomy
carcinoma
bladder cancer, squamous cell carcinoma
cancer
measurable disease
  • 15 views
  • 14 Jul, 2022
  • 14 locations
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment of NSCLC

  • 0 views
  • 01 Oct, 2021
  • 1 location
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) inhibitors, has revolutionized the treatment of

  • 0 views
  • 07 Oct, 2021
  • 1 location
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of your immune system by shutting it down. Nivolumab is a type of antibody that is specific for

HIV Vaccine
antiretroviral
cancer chemotherapy
nivolumab
cancer
  • 226 views
  • 12 Jul, 2022
  • 23 locations
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Objectives To evaluate the efficacy, in terms of tumor shrinkage, objective response rate, and down-stage rate, of nivolumab + ipilimumab as neoadjuvant therapy for patients with HCC; To evaluate the safety profile in patients with HCC who receive neoadjuvant nivolumab + ipilimumab treatment; To collect HCC tumor tissue and peripheral …

  • 2 views
  • 27 Jan, 2021
  • 8 locations
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma

Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an unusually high rate of young-onset pancreatic carcinoma. Pancreatic ductal adenocarcinoma is by far the …

  • 0 views
  • 24 Mar, 2022
  • 1 location
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies

by loss of function mutations in the LRBA (encoding lipopolysaccharide-responsive beige like anchor protein) and CTLA4 (encoding cytotoxic T lymphocyte antigen 4) genes, which are in common

  • 42 views
  • 25 Jan, 2021
  • 1 location
The Clinical Implications of Immune Checkpoint Pathways in PCNSL

been identified. Among them, three have been studied most intensively: cytotoxic T lymphocyte antigen 4 (CTLA4) binding to CD80 or CD86, programmed cell death protein 1 (PD-1) binding to PD-1 ligand 1

cancer
hodgkin's disease
gm-csf
colony stimulating factor
  • 0 views
  • 17 Feb, 2022
  • 1 location